NASDAQ:ADAPAdaptimmune Therapeutics Stock Price, Forecast & News

Adaptimmune Therapeutics' stock was trading at $2.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ADAP shares have increased by 213.9% and is now trading at $9.23. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Adaptimmune Therapeutics.

Adaptimmune Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Adaptimmune Therapeutics.

Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) released its quarterly earnings results on Thursday, May, 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.01. The biotechnology company earned $0.76 million during the quarter, compared to analysts' expectations of $25.90 million. Adaptimmune Therapeutics had a negative net margin of 7,324.48% and a negative return on equity of 85.62%. View Adaptimmune Therapeutics' earnings history.

5 Wall Street analysts have issued twelve-month target prices for Adaptimmune Therapeutics' stock. Their forecasts range from $5.00 to $9.00. On average, they expect Adaptimmune Therapeutics' stock price to reach $7.00 in the next twelve months. This suggests that the stock has a possible downside of 24.2%. View analysts' price targets for Adaptimmune Therapeutics.

News coverage about ADAP stock has trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Adaptimmune Therapeutics earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Adaptimmune Therapeutics.

Some companies that are related to Adaptimmune Therapeutics include Spark Therapeutics (ONCE), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), Halozyme Therapeutics (HALO), bluebird bio (BLUE), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Immunovant (IMVT), Alector (ALEC), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX) and Adverum Biotechnologies (ADVM). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), BlackRock (BLK), Shopify (SHOP), Cara Therapeutics (CARA), Micron Technology (MU) and Chipotle Mexican Grill (CMG).

(ADAP) raised $150 million in an initial public offering on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ADAP stock can currently be purchased for approximately $9.23.

Adaptimmune Therapeutics has a market capitalization of $1.20 billion and generates $1.12 million in revenue each year. The biotechnology company earns $-137,160,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. Adaptimmune Therapeutics employs 406 workers across the globe.

The official website for Adaptimmune Therapeutics is www.adaptimmune.com.

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected]